Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

People In Brief

This article was originally published in The Gray Sheet

Executive Summary

American Medical Systems: Martin Emerson assumes Minnetonka, Minn. firm's president & CEO spot effective Jan. 5, replacing Douglas Kohrs, who will remain chairman of AMS' board. A 20-year device industry veteran, Emerson has spent his last four years at American Medical Systems in various executive roles, including VP-general manager of international, exec VP-global sales & marketing and chief operating officer. His previous career experience includes stints at Baxter International and Boston Scientific. Currently, AMS is preparing a PMA supplement for its TherMatrx TMx-2000 BPH thermotherapy system (1"The Gray Sheet" Nov. 8, 2004, p. 6)...

You may also be interested in...



BioSphere Benefits From Broader UFE Awareness, But Remains Short On Profit

Uterine fibroid embolic device maker BioSphere Medical credits Q4 revenue growth to a series of favorable technology assessments, improved marketing management and a high-profile procedure

BioSphere Benefits From Broader UFE Awareness, But Remains Short On Profit

Uterine fibroid embolic device maker BioSphere Medical credits Q4 revenue growth to a series of favorable technology assessments, improved marketing management and a high-profile procedure

Sales & Earnings In Brief

Zimmer/Centerpulse anniversary: Combined sales for Q3 are $700 mil., a 13% increase over the prior-year period, when the firms remained stand-alone entities. Little over a year after the Centerpulse acquisition, Zimmer CEO Ray Elliott stresses in an Oct. 25 call that an estimated loss of $50 mil. in sales dissynergies and distributor returns failed to hamper "sequentially solid" results in "global reconstructive procedure-and-mix growth." The company booked 16% growth in combined sales of reconstructive products in the third quarter, exactly level with Q2 figures. "If we adjust the second quarter for European distributor returns within the integration process, then [Q2] outgrew the first quarter, and a recently completed third quarter outgrew them both on a daily basis," he adds. To recover sales lost to dissynergies, Zimmer will implement "cross-training benefits which should accrue to our favor later in 2005." Elliott acknowledges that the firm's "toughest challenge" lies in Q4, because "to reach management's new range of $775 mil.-$780 mil. in sales, we now face a comparison to the fourth quarter of 2003 that had zero distributor returns." Zimmer's Q4 guidance is further challenged by a $9 mil. "overstatement" due to a miscalculation, the firm notes...

Related Content

UsernamePublicRestriction

Register

MT021420

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel